Kurt Von Emster Sells 37,754 Shares of Crispr Therapeutics AG (CRSP) Stock

Crispr Therapeutics AG (NASDAQ:CRSP) Director Kurt Von Emster sold 37,754 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $26.76, for a total value of $1,010,297.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.39 during trading on Thursday, reaching $23.91. The company had a trading volume of 706,365 shares, compared to its average volume of 998,167. The firm has a market capitalization of $987.75 and a price-to-earnings ratio of -74.72. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $27.39.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business’s revenue was up 54.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.77) earnings per share. research analysts forecast that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Hershey Trust Co. acquired a new stake in Crispr Therapeutics during the third quarter worth about $768,000. Tiff Advisory Services Inc. purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $505,000. Adams Street Partners LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $1,019,000. Granahan Investment Management Inc. MA boosted its position in shares of Crispr Therapeutics by 51.7% in the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after buying an additional 89,839 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $2,384,000. Institutional investors own 24.52% of the company’s stock.

CRSP has been the topic of several recent research reports. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Piper Jaffray Companies initiated coverage on Crispr Therapeutics in a research report on Friday, December 22nd. They issued an “overweight” rating on the stock. SunTrust Banks restated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Barclays restated a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research report on Friday, September 8th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $22.38.

ILLEGAL ACTIVITY NOTICE: “Kurt Von Emster Sells 37,754 Shares of Crispr Therapeutics AG (CRSP) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/kurt-von-emster-sells-37754-shares-of-crispr-therapeutics-ag-crsp-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply